Subbiah V, Wolf J, Konda B, Kang H, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET
fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001):
a phase 1/2, open-label, basket trial. Lancet Oncol 2022;23:1261-1273.
PMID: 36108661